Bipolar I disorder

Bipolar I disorder is a chronic mental illness characterized by the occurrence of at least one manic episode, typically alternating with depressive episodes, and is associated with significant functional impairment and increased risk of suicide.

Definition and Diagnostic Criteria

Bipolar I disorder is classified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) under the category of bipolar and related disorders. The core feature is the presence of a manic episode that lasts for at least one week (or requires hospitalization), during which an individual exhibits an abnormally elevated, expansive, or irritable mood and increased goal-directed activity or energy. The manic episode must cause marked impairment in social or occupational functioning, or necessitate hospitalization to prevent harm to self or others, or include psychotic features. While depressive episodes are common in bipolar I disorder, they are not required for diagnosis. However, the majority of individuals with bipolar I disorder experience major depressive episodes over the course of their illness.

Epidemiology

Bipolar I disorder has a lifetime prevalence of approximately 0.6% to 1.0% of the general population globally. It affects men and women equally, although women may experience more depressive episodes and rapid cycling. The disorder often emerges in late adolescence or early adulthood, with the average age of onset being around 18 to 20 years. There is a strong genetic component, with first-degree relatives of affected individuals having a significantly elevated risk.

Etiology and Pathophysiology

The exact cause of bipolar I disorder is unknown, but it is understood to result from a complex interplay of genetic, neurobiological, and environmental factors. Family, twin, and adoption studies have demonstrated high heritability, with estimates ranging from 60% to 85%. Several genetic variants, particularly those involving ion channel genes, neurotransmitter systems (e.g., dopamine, serotonin, and glutamate), and circadian rhythm regulators, have been implicated. Neuroimaging studies reveal structural and functional abnormalities in brain regions involved in emotional regulation, such as the prefrontal cortex, amygdala, and hippocampus. Dysregulation of intracellular signaling pathways, including the protein kinase C and glycogen synthase kinase-3 systems, is also thought to contribute. Environmental triggers, such as stressful life events, sleep disruption, and substance use, can precipitate the first episode and subsequent relapses.

Clinical Features

Manic Episode

A manic episode is defined by a distinct period of abnormally elevated, expansive, or irritable mood lasting at least one week and accompanied by three or more of the following symptoms (four if mood is only irritable): inflated self-esteem or grandiosity, decreased need for sleep, increased talkativeness, flight of ideas or racing thoughts, distractibility, increased goal-directed activity or psychomotor agitation, and excessive involvement in risky activities (e.g., spending sprees, sexual indiscretions, or impulsive business investments). During a manic episode, the individual's behavior is often markedly different from their usual baseline, and judgment is impaired. Psychotic features, such as delusions (often grandiose or persecutory) or hallucinations, may occur.

Hypomanic Episode

Hypomania is a milder form of mania that lasts at least four consecutive days. Unlike mania, a hypomanic episode does not cause marked impairment in functioning, does not require hospitalization, and does not include psychotic features. However, it can still be distressing to the individual and often precedes or follows a depressive episode.

Depressive Episode

A major depressive episode in bipolar I disorder shares the same criteria as unipolar depression: depressed mood or loss of interest or pleasure for at least two weeks, accompanied by symptoms such as significant weight or appetite changes, sleep disturbance, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, concentration difficulties, and recurrent thoughts of death or suicide. The presence of depressive episodes in bipolar I disorder can be severe and contribute to a high burden of illness.

Mixed Episodes

In DSM-5, the category of "mixed episode" was replaced by the specifier "with mixed features," which can be applied to manic, hypomanic, or depressive episodes when symptoms of the opposite polarity are present concurrently (e.g., a manic episode with three or more depressive symptoms). Mixed states are particularly challenging to treat and are associated with a higher risk of suicide.

Course and Prognosis

Bipolar I disorder is a lifelong condition with a highly variable course. Most individuals experience recurrent episodes, with an average of 8-10 episodes over a lifetime. The duration and frequency of episodes can vary widely. Between episodes, many individuals may return to a stable, euthymic state, but residual symptoms and functional impairment are common. Rapid cycling, defined as four or more episodes within a 12-month period, occurs in 10-20% of patients and is associated with a worse prognosis. Suicide risk is significant, with estimates suggesting that 10-15% of individuals with bipolar I disorder die by suicide. Substance use disorders, anxiety disorders, and medical comorbidities (e.g., cardiovascular disease, diabetes) are frequently co-occurring and can complicate management.

Diagnosis and Assessment

The diagnosis of bipolar I disorder relies on a thorough clinical interview, including a detailed history of past mood episodes, family history, and collateral information from family members or caregivers. Structured diagnostic instruments, such as the Structured Clinical Interview for DSM-5 (SCID-5), can aid in assessment. It is crucial to distinguish bipolar I disorder from other conditions that may present with similar symptoms, such as unipolar depression (especially when the first episode is depressive), schizophrenia, schizoaffective disorder, substance-induced mood disorder, and borderline personality disorder. Medical evaluation is necessary to rule out organic causes, such as thyroid dysfunction, neurologic conditions, or medication-induced mood changes.

Treatment

Pharmacotherapy

Mood stabilizers are the cornerstone of treatment for bipolar I disorder. Lithium is the most well-established mood stabilizer and is effective in reducing the risk of manic and depressive relapse. It also has a specific anti-suicidal effect. Valproate (divalproex) and carbamazepine are alternative first-line options, particularly for acute mania. Atypical antipsychotics, such as olanzapine, quetiapine, risperidone, and aripiprazole, are widely used for acute manic episodes and long-term maintenance. Quetiapine and lamotrigine have demonstrated efficacy in the treatment and prevention of depressive episodes. The combination of a mood stabilizer and an antipsychotic is often required for severe mania or psychotic features. Antidepressants are generally used cautiously due to the risk of precipitating manic episodes or rapid cycling.

Psychotherapy

Psychosocial interventions play an essential role in the management of bipolar I disorder. Cognitive-behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), family-focused therapy, and psychoeducation have been shown to improve medication adherence, reduce relapse rates, and enhance functioning. These therapies often focus on early recognition of mood episode prodromes, stress management, sleep hygiene, and strengthening social support.

Electroconvulsive Therapy (ECT)

ECT is a highly effective treatment for severe manic or depressive episodes that are refractory to pharmacotherapy, or when rapid response is needed (e.g., due to catatonia, psychosis, or high suicide risk). It may also be considered for mixed episodes.

Challenges and Comorbidities

Managing bipolar I disorder is complicated by high rates of non-adherence to medication, often due to side effects, lack of insight during manic episodes, or the desire for the euphoric features of hypomania. Substance use disorders, particularly alcohol and cannabis misuse, are common and worsen the course of illness. Anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and medical conditions such as metabolic syndrome are frequent comorbid conditions that require integrated treatment approaches.

Research and Future Directions

Ongoing research aims to better understand the neurobiological underpinnings of bipolar I disorder through genetic studies, neuroimaging, and biomarker identification. Advances in personalized medicine may enable more targeted treatment selection based on individual genetic and clinical profiles. Developments in digital health, such as smartphone-based monitoring of mood, sleep, and activity, hold promise for early detection of relapse and remote intervention. The continued exploration of novel pharmacological targets, including anti-inflammatory agents and agents modulating glutamate signaling, may yield new therapeutic options.

See Also

• Bipolar disorder
• Bipolar II disorder
• Cyclothymic disorder
• Major depressive disorder
• Mood stabilizers

References

(References omitted per instructions, but in a real encyclopedia entry, this section would list peer-reviewed literature, DSM-5, and authoritative texts such as The American Psychiatric Association Publishing Textbook of Psychiatry or Goodwin & Jamison’s Manic-Depressive Illness.)